PMID: 15375498Sep 18, 2004Paper

Hearing function in soft tissue sarcoma patients after treatment with carboplatin: a report from the Late Effects Surveillance System

Oncology Reports
W StöhrJ D Beck

Abstract

The aim of this study was to analyse carboplatin-induced ototoxicity in a recent study trial. Twenty patients who had received carboplatin for the treatment of soft tissue sarcoma were investigated prospectively for ototoxicity in a multi-centre trial. Hearing function was tested by audiometry. All patients but one were treated with a cumulative dose of 1500 mg/m(2), the remaining with 500 mg/m(2). We evaluated the incidence and dependencies of hearing loss, and compared hearing thresholds to those of an untreated control group (n=60). Hearing thresholds in the carboplatin treated group were only marginally poorer compared with those of the control group. After carboplatin therapy no patient (0%; 95%-KI: 0-17%) had a hearing loss >20 dB. Hearing thresholds were not dependent on age, sex or cranial irradiation. We conclude that ototoxicity after carboplatin was low in our group of patients.

Related Concepts

Related Feeds

Auditory Perception

Auditory perception is the ability to receive and interpret information attained by the ears. Here is the latest research on factors and underlying mechanisms that influence auditory perception.

Related Papers

Cancer Investigation
W StöhrGerman Late Effects Working Group in the German Society of Pediatric Oncology and Hematology
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Ibrahim QaddoumiCarlos Rodriguez-Galindo
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
M J SchellW H Meyer
© 2021 Meta ULC. All rights reserved